Stay updated with breaking news from Daniel Alkon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative...
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update - Data Safety Monitoring Board confirms Bryostatin-1 Safety News provided by Share this article Share this article NEW YORK, June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD"). To date, the Company has ...
Press release content from PR Newswire. The AP news staff was not involved in its creation. Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum April 26, 2021 GMT NEW YORK, April 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Daniel Alkon, the Company’s President and Chief Scientific Officer, will present a “Spotlight Showcase” of Synaptogenix under the title “Regenerative Therapeutics...
Synaptogenix to Present at Upcoming Scientific Industry Conferences News provided by Share this article Share this article NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will attend two upcoming scientific industry conferences. On Thursday, February 25 th, Dr. Daniel Alkon M.D., President and Chief Scientific Officer, will present a virtual poster at the 9 th annual Neurodegenerative Drug Development Summit. The virtual posters begin at 5...
New Study Demonstrates Bryostatin Normalizes Autistic Spectrum Behaviors in Mice - Peer Reviewed Article Published through Nature.com News provided by Share this article Share this article NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced a new report published by "Scientific Reports," an open-access journal publishing peer reviewed research through Nature.com, titled "Chronic Bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice." This new study, in collaboration with the Fragile X Foundation and s...